About this trial
Last updated 14 years ago
Study ID
VCL-1005-208
Status
Completed
Type
Interventional
Phase
Phase 2
Placebo
No
Accepting
18+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 21 years ago
What is this trial about?
The purpose of this clinical trial is to determine if Allovectin-7®, an experimental
gene-based immunotherapy, can shrink melanoma tumors. The trial will also examine if this
treatment can improve the time to disease progression.
What are the Participation Requirements?
In order to be in this trial, you must meet the enrollment criteria. Below is a list of
some of the enrollment criteria.
- You have been diagnosed with Stage III or Stage IV melanoma
- Your cancer has returned after a prior treatment (e.g. radiation or chemotherapy) or
you refused therapy with standard treatment
- You are able to carry out your normal daily activities
- Your melanoma has not spread to your brain